Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664516 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
A Phase 2 study of Binge-Eating Disorder, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05664516: Recruiting Phase 2 study of Binge-Eating Disorder, sponsored by Massachusetts General Hospital.
NCT05664516 is a Phase 2 study of Binge-Eating Disorder that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 1,142-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05664516, a Phase 2 study of Binge-Eating Disorder, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the impact of intranasal oxytocin vs placebo in patients with binge eating disorder or episodes of binging. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \[reduction in bingeing frequency\], and have a satisfactory safety and tolerability profile. We will also explore the predictive value of changes in homeostatic appetite, reward sensitivity, and impulse control, the identified underlying mediators, as assessed 4 weeks into the intervention, for treatment success after 8 weeks of the intervention.
Primary Outcome
Change in binge frequency as assessed by the Eating Disorder Examination clinical interview
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TNX-1900 (Tonix Pharmaceuticals)
Study Locations (1)
Massachusetts
- Neuroendocrine Unit Research Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05664516 shows while recruiting
NCT05664516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,142-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05664516 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05664516 about?
NCT05664516 is a clinical study titled "A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder". This study evaluates the impact of intranasal oxytocin vs placebo in patients with binge eating disorder or episodes of binging. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \[reduction in bingeing frequency\], and have a satisfactory safety and tolera...
What is the current status of trial NCT05664516?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-03-07. Estimated completion is 2026-12.
What conditions does trial NCT05664516 study?
This clinical trial studies the following conditions: Binge-Eating Disorder.
What interventions are being tested in trial NCT05664516?
The interventions under investigation include: Placebo (DRUG), TNX-1900 (Tonix Pharmaceuticals) (DRUG).
Who is sponsoring clinical trial NCT05664516?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05664516 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Binge-Eating Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05664516's enrollment target sits among peer trials
60 24th of 37 higher than 13 of 37 other Binge-Eating Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Binge-Eating Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
RECRUITING · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
COMPLETED · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
COMPLETED · Phase 2
-
Dasotraline Binge Eating Disorder Study
COMPLETED · Phase 2
-
Vortioxetine for Binge Eating Disorder
COMPLETED · Phase 2
-
Craving, Binge Eating and Obesity
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI